<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786901</url>
  </required_header>
  <id_info>
    <org_study_id>875</org_study_id>
    <nct_id>NCT02786901</nct_id>
  </id_info>
  <brief_title>LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</brief_title>
  <official_title>A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of
      Ocular Inflammation and Pain Following Cataract Surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, Multi-Center, Double-Masked, Vehicle Controlled, Randomized, Parallel-Group Study
      to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the
      Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 13, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with complete resolution of AC cells at visit 5</measure>
    <time_frame>8 days</time_frame>
    <description>Will be tested using the Pearson Chi-squared tests with p-values adjusted using Bonferroni-based tree gatekeeping strategy.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Cataract</condition>
  <condition>Pain</condition>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate Ophthalmic Gel dosed TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate Ophthalmic Gel dosed BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel dosed TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel dosed BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate Ophthalmic Gel dosed TID</intervention_name>
    <description>Gel</description>
    <arm_group_label>Loteprednol Etabonate Ophthalmic Gel dosed TID</arm_group_label>
    <other_name>LE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate Ophthalmic Gel dosed BID</intervention_name>
    <description>Gel</description>
    <arm_group_label>Loteprednol Etabonate Ophthalmic Gel dosed BID</arm_group_label>
    <other_name>LE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel dosed TID</intervention_name>
    <description>Gel</description>
    <arm_group_label>Vehicle Gel dosed TID</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel dosed BID</intervention_name>
    <description>Gel</description>
    <arm_group_label>Vehicle Gel dosed BID</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and with
             the capacity to provide voluntary informed consent.

          2. Be able to read, understand, and provide written informed consent on the Institutional
             Review Board (IRB)/Ethics Committee (EC) approved ICF and provide Health Insurance
             Portability and Accountability Act (HIPAA) authorization.

          3. Be willing and able to comply with all treatment and follow-up/study procedures.

          4. Be a candidate for routine, uncomplicated cataract surgery (phaco-emulsification with
             posterior chamber intraocular lens [IOL] implantation, not combined with any other
             surgery).

          5. In the Investigator's opinion, have potential postoperative pin-holed Snellen visual
             acuity (VA) of at least 20/200 in the study eye at Visit 1 (Screening) and at least
             20/200 in the fellow eye.

        Key Exclusion Criteria:

          1. Have a severe/serious ocular condition or history/presence of chronic generalized
             systemic disease that the Investigator feels might increase the risk to the subject or
             confound the result(s) of the study.

          2. Be a female subject who is pregnant or breastfeeding.

          3. Be monocular (fellow eye is nonfunctional or fellow eye's pinhole vision is worse than
             Snellen 20/200).

          4. Have had ocular surgery (including laser surgery) in the study eye within 3 months or
             in the fellow eye within 2 weeks prior to Visit 1 (Screening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Ramjit</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 03</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 05</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 04</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 06</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <disposition_first_submitted>April 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 10, 2018</disposition_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

